Skip to main content

Table 3 Clinical and pathologic features in patients with low risk prostate cancer, eligible for active surveillance, who elected treatment with radical prostatectomy (2007–2014)

From: Impact of bilateral biopsy-detected prostate cancer on an active surveillance population

Variable

Unilateral at biopsy

(n = 186)

Bilateral at biopsy

(n = 25)

p value

Clinical Presentation

median (IQR)

median (IQR)

Age (years)

58 (54–64)

58 (55–61)

0.78

PSA (ng/ml)

5 (4–6.6)

4.6 (4.2–5.9)

0.51

PSAD

0.12 (0.088–0.17)

0.14 (0.1–0.18)

0.48

BMI (kg/m2)

29 (25.8–31.8)

28.3 (25–33)

0.86

US Vol (mL)

41.7 (32.6–53.2)

35 (25–42)

0.03

Max core inv.%

8 (5–20)

8 (5–10)

0.95

Grade Group

1

1

Stage

  

1

 T1c

172 (92.5%)

24 (96%)

 T2a

14 (7.5%)

1 (4%)

RP Pathology

  

Prostate weight (g)

45.4 (26–56.3)

42.5 (34.1–52.9)

0.28

Grade Group (Gleason)

  

0.37

 GG1 (3 + 3)

106 (57%)

15 (60%)

 GG2 (3 + 4)

72 (39%)

8 (32%)

 GG3 (4 + 3)

6 (3%)

1 (4%)

 GG4 (4 + 4)

1 (0.5%)

1 (4%)

 GG5 (4 + 5)

1 (0.5%)

0

Upgrading

80 (43%)

10 (40%)

% of tumor

4%

5%

0.11

Pathologic Stage

  

0.49

 pT2a

44 (23.7%)

3 (12%)

 pT2b

2 (1.1%)

0

 pT2c

136 (73.1%)

22 (88%)

 pT3a

4 (2.1%)

0

 pT3b

0

0

  1. Prostate Specific Antigen (PSA), Prostate Specific Antigen Density (PSAD) Body Max Index (BMI), Radical Prostatectomy (RP)